PEGIPANERMIN
Mild Cognitive Impairment (MCI)
Inmune Bio, Inc.protein_peptidePhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 31/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the Mild Cognitive Impairment (MCI) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Namenda University of California, Los Angeles | Phase 4 | BB |
Cipralex University of California, Los Angeles | Phase 4 | BB |
LITHIUM, ELEMENTAL University of Chile | Phase 4 | B |
Tebofortan Fundació ACE Institut Català de Neurociències Aplicades | Phase 4 | B |
Donanemab Eli Lilly and Company | Phase 3 | B |
View all 22 →
Same molecule, other indications
PEGIPANERMIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →